DERIVATE-ICM registry

DERIVATE is an international, multicenter, multivendor observational registry (NCT03352648) led from Centro Cardiologico Monzino in Milan. It enrolled patients with chronic heart failure and reduced ejection fraction who had clinical work-up, transthoracic echocardiography and cardiac MRI, and followed them for arrhythmic events and death. The ischemic cardiomyopathy arm (DERIVATE-ICM) asked whether cardiac MRI reclassifies who should get a preventive implantable cardioverter-defibrillator better than the usual echocardiographic ejection fraction cutoff of 35%. A restricted Zenodo record holds the raw data behind the paper; it lists no files and does not say whether images are included.

Composition

861 patients with ischemic cardiomyopathy, chronic heart failure and an echocardiographic ejection fraction below 50%. Mean age 65 years (SD 11), 86% men. Over a median follow-up of 1,054 days, 88 patients (10.2%) had a major adverse arrhythmic cardiac event, the primary endpoint.

Acquisition

The paper reports cardiac MRI measures of left ventricular volume and ejection fraction from cine imaging and the mass of late gadolinium enhancement, acquired on scanners from more than one vendor across several centers. The trial registration lists 33 sites in 6 countries in Europe and North America for the whole registry, which also includes non-ischemic dilated cardiomyopathy. The registration also names T1 mapping and extracellular volume among the planned measures; the abstract of the ICM paper does not report them.

Annotations

Each patient has outcome data (arrhythmic events during follow-up) together with derived MRI measures such as end-diastolic volume index, ejection fraction and scar mass. No image-level labels are described.

Known limitations

• Access is restricted with no published license, terms or request process; content of the record is unknown.
• Field strengths, vendors and per-site counts were not available from an open source and are left out.
• Exclusions (recent infarction, severe valve disease, other cardiomyopathies, low kidney function and others) limit the cohort to stable patients who could receive gadolinium.